Thursday, December 11, 2008

BioSante Pharmaceuticals Signs Elestrin U.S. Marketing Agreement With Azur Pharma

Azur Pharmaceuticals Deal: BioSante Pharmaceuticals, Inc for the marketing of Elestrin (estradiol gel) to treat moderate-to-severe hot flashes in menopausal women in the United States. Upon execution of the agreement, BioSante received $3.325 million comprised of a $0.5 million product licensing fee and $2.825 million for transfer of the Elestrin trademark and inventories, among other items.

The details can be read here.

No comments: